Intellectual Property

Sistemic place great emphasis on the development and protection of intellectual property. Sistemic’s strategy is focused on obtaining broad protection for our technologies and coverage in key territories. As part of this strategy, we have claimed composition of matter and methods of using non-coding RNAs for drug repositioning, biomarkers development and as quality metrics of somatic and stem cells, including the use of miRNA’s in the clinical and commercial development of cells and the use of functional features of cells for non-therapeutic applications.

Applications are in the National Phase in the United States, Europe, Japan, Korea, Israel, Australia, Brazil, China and Canada.